Fulminant myocarditis is a rare inflammatory heart disease affecting relatively young adults. We describe a case of a 27-year-old male with acute onset severe heart failure. A rapid and accurate diagnostic approach suggested parvovirus B19 as the most probable cause for this fulminant viral myocarditis. Initial haemodynamic support, intensive immunosuppressive and antiviral therapy resulted in a complete recovery within 2 weeks. This case demonstrates the importance of a detailed diagnosis, allowing better classification of the underlying pathology and subsequent targeted treatment.
The rare inflammatory heart disease fulminant myocarditis affects relatively young adults. Here, a case of a 27-year-old male with acute onset severe heart failure is described. Parvovirus B19 (PVB19) was suggested as the most probable cause for this fulminant viral myocarditis after a rapid and accurate diagnostic approach. The present case highlights the importance of a detailed diagnosis, allowing better classification of the underlying pathology and subsequent targeted treatment, possibly leading to a better outcome.
Case description
A 27-year-old male was admitted to the Cardiology Department of the Maastricht University Medical Centre (Maastricht, the Netherlands) with signs of acute onset progressive heart failure (New York Heart Association class III-IV). His medical history revealed Crohn's disease, for which he was treated with azathioprine and intermittent infliximab (last dose 2 months before the current presentation). For 10 days, the patient experienced flu-like symptoms, such as a non-productive cough, fatigue, myalgia and fever. Physical examination demonstrated a febrile temperature of 39°C and signs of compromised circulation (heart rate of 120 beats per min, blood pressure of 90/60 mmHg and respiratory rate of 25 breaths per min). The chest X-ray indicated a normal cardiothoracic ratio, without signs of infiltrates or congestion. Electrocardiography revealed atrial fibrillation and a complete left bundle branch block. Initial laboratory results (Table 1) showed extensive myocardial damage and signs of infectious disease.
Microbiological screening of the serum tested positive for PVB19 (437 copies/ml) without detection of other cardiotrophic viruses (such as human herpes virus 6, Epstein-Barr virus, adenovirus, enterovirus or cytomegalovirus). Blood cultures yielded no bacterial or fungal growth. Cardiac function was severely depressed, with a left ventricular ejection fraction of 20% on echocardiography, without cardiac dilatation. A coronary angiography excluded an acute coronary syndrome and subsequent right ventricular endomyocardial biopsies (EMBs) were taken at presentation and recovery ( Figure 1 ). These EMBs revealed extensive infiltration of inflammatory cells in combination with extensive degradation of cardiomyocytes ( Figure 1A and 1B) . The diagnosis of virusassociated acute fulminant myocarditis was further suggested by a high myocardial PVB19 load (14,931 copies/ µg DNA) by PCR assay and a positive signal in endothelial cells with PVB19 immunostaining compared with controls omitting PVB19 antibody (Figure 2 Introduction magnetic resonance imaging performed 1 week after presentation showed increased signal intensity at the septal wall on T2-weighted images, suggestive of oedema and active inflammation ( Figure 3A ). Late enhancement images revealed patchy mid-myocardial hyperenhancement at the basal and mid-septal level, in addition to several circumscript small intramyocardial regions of anterior and inferior segments ( Figure 3B ). Supportive therapy with inotropics (dobutamine 10 µg/kg/min) and an intra-aortic balloon pump were necessary to maintain sufficient cardiac output. with intravenous immunoglobulin (0.5 g/kg/day) and aciclovir (2.1 g/day), and immunosuppressive therapy with intravenous prednisolon (50 mg/day) was started to terminate the underlying viral infection and immune dysregulation. Under this broad therapeutic approach, the patient remained stable and gradually recovered over the next 2 weeks. His left ventricular ejection fraction increased to 50%, the cardiac biomarkers normalized and control EMBs revealed no active myocarditis ( Figure   1C and 1D) with a decrease in myocardial PVB19 load to 2.933 copies/µg DNA. The patient was discharged in a stable clinical condition. Standard heart failure medication was initiated and immunosuppressive therapy for his Crohn's disease was continued. A follow-up at the Cardiology department of the Maastricht University Medical Centre (Maastricht, the Netherlands) was advised to monitor signs of recurrence or development of chronic heart failure.
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Diagnosis
Acute myocarditis is an inflammatory process involving the myocardium, with a variable clinical presentation. The disease is distinguished on the basis of clinical presentation: fulminant and non-fulminant [1] . This case report describes a PVB19-induced fulminant viral myocarditis in a previously immunocompromised patient. Myocarditis is found during autopsy in up to 42% of cases with unexplained deaths in patients younger than 35 years, indicating the extent of the disease [2] . The exact incidence and prevalence of fulminant myocarditis remain unknown, but it is seen in 10% of all patients with biopsy-proven myocarditis [3] . The underlying aetiology and pathophysiology of fulminant and non-fulminant myocarditis are thought to be similar, and are associated with different infections, systemic diseases and/or exposure to various drugs and toxins. Viruses, especially PVB19, enteroviruses and human herpes virus 6, are the most common causes of acute myocarditis in developed countries [4] .
There is conflicting evidence regarding whether a fulminant myocarditis can arise from an existing autoimmune disorder (such as Crohn's disease) or whether it can be a side effect of treatment with infliximab [5] . Fulminant myocarditis might be associated with a PVB19 infection because myocardial endothelial cells have been described as target cells of a PVB19 infection [6] . Symptoms started with a flu-like episode and a high PVB19 load was found in the myocardium and blood samples in conjunction with a positive signal in endothelial cells on PVB19 immunostainings, indicating active PVB19 as the most probable cause for the fulmunant myocarditis in the present case. Furthermore, the patient's last infliximab therapy ended 2 months prior to presentation.
The symptoms associated with fulminant myocarditis are distinct. Patients often experience flu-like symptoms, either of the upper respiratory or gastrointestinal tract, before any cardiac symptoms appear. They commonly present with acute onset heart failure, ventricular arrhythmias or pseudo-myocardial infarction [1] .
An accurate and rapid diagnositc approach is crucial for the optimal management of fulminant myocarditis [7] . Cardiac magnetic resonance imaging can be helpful in the diagnosis of acute myocarditis, although initial haemodynamic instability frequently hinders this technique. Coronary angiography should be performed to exclude coronary artery disease. Subsequent EMBs play a crucial role in the evaluation of patients with acute onset heart failure with haemodynamic compromise, providing unique diagnostic and prognostic information and allowing differentiation between fulminant lymphocytic myocarditis, giant cell myocarditis and necrotizing eosinophilic myocarditis. Giant cell myocarditis and necrotizing eosinophilic myocarditis are associated with a poor prognosis, whereas patients with fulminant lymphocytic myocarditis, once having survived the initial episode, have an excellent longterm prognosis of 93% at 11 years [1] . Additional viral PCR for quantification of viral genome and immunohistochemistry for cardiac inflammation and necrosis should be performed [3] . This results in a better classification of the underlying pathophysiology and better aetiology-based treatment options.
Treatment and management
Evidence-based guidelines for the treatment of fulminant myocarditis are lacking. The current consensus in management is solely based on observational studies [1, 3, 8] . Intense haemodynamic supportive therapy is highly beneficial in patients with fulminant myocarditis. Patients are often in cardiovascular shock and require intravenous inotropic agents and intra-aortic balloon pumps for circulatory support. In case of persistent or worsening haemodynamic instability, a ventricular assistance device can be a bridge to recovery or even heart transplantation [3] .
The roles of additional immunosuppressive and antiviral therapy during the acute phase of fulminant myocarditis remain unclear. Previous trials using these treatment modalities did not enrol patients with fulminant myocarditis [9, 10] because of its low clinical event rate; therefore, controversy still exists regarding whether patients presenting with fulminant myocarditis should receive aggressive immunosuppressive and antiviral therapy. Nevertheless, it can be hypothesized that preventing direct viral damage using antiviral therapy or by the inhibition of viral proliferation by interfering with the interaction of viruses and their cellular receptor and signalling amplification systems (thus preventing autoimmune dysregulation in the acute phase), might result in a better clinical outcome [3] . Because up to 7% of the patients presenting with fulminant myocarditis still have a fatal outcome despite optimal supportive therapy, additional immunosuppressive and antiviral treatment must be considered [1] .
After the acute phase, standard heart failure medication, such as β-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and aldosterone antagonists, should be started. Outpatient clinic follow-up is advised because myocarditis might recur many years after the initial episode.
Conclusions
This case illustrates a young male with a fulminant lymphocytic myocarditis associated with an active cardiac PVB19 infection. Treatment with aggressive haemodynamic support in conjunction with immunosuppressive and antiviral therapy resulted in complete recovery. Fulminant myocarditis is an uncommon inflammatory heart disease with a distinct clinical entity. A rapid and accurate diagnostic approach is crucial to its optimal mangement, and includes EMBs to evaluate the presence of cardiac inflammation and viral infection. Although the majority of patients show complete recovery with initial haemodynamic support, a subgroup still progresses to a fatal outcome. Currently, the effect of additional immunosuppressive and antiviral therapy remains unclear. Future randomized placebo-controlled clinical trials based on EMB are needed to provide the evidence for these novel therapeutic options in this selected group of patients.
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